Nykode Therapeutics Stock
Stocks
VACC
NO0010714785
Biotechnology & Medical Research
OTC Markets Traded|
Real-time
Oslo Bors
03:34:13 2026-09-07 EDT
|
5-day change | 1st Jan Change | ||
| 4.015 NOK | -1.95% |
|
-6.41% | +66.46% |
| 08-28 | Nykode Therapeutics Raises NOK286 Million via Share Placement | MT |
| 08-27 | ABG Sundal Collier raises the target price for Nykode Therapeutics to 7.0 Norwegian kroner (4.5), reiterates buy | FW |
| Market Cap | 1.34B 144M 124M 116M 106M 199M 13.58B 200M 1.38B 534M 6.97B 540M 528M 22.44B | P/E 2026 * |
-6.29x | P/E 2027 * | 84.4x |
|---|---|---|---|---|---|
| Enterprise Value | 853M 91.74M 78.94M 74.27M 67.85M 127M 8.66B 127M 878M 341M 4.44B 344M 337M 14.32B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 3.38x |
| Free-Float |
76.21% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Oslo Bors
| VACC | Real-time | |
CBOE
| Real-time | ||
|
Nasdaq Stockholm
| NYKD O | Delayed | |
|
OTC Markets
| VACBF | Delayed | |
|
Börse Stuttgart
| 5VB | Delayed | |
|
Boerse Muenchen
| 5VB | Real-time | |
|
Deutsche Boerse AG
| 5VB | Delayed | |
|
CBOE
| Real-time |
Last Transcript : Nykode Therapeutics
| 1 day | -1.95% | ||
| 1 week | -6.41% | ||
| Current month | -6.41% | ||
| 1 month | +20.57% | ||
| 3 months | +26.46% | ||
| 6 months | +28.69% | ||
| Current year | +66.46% |
| 1 week | 3.98 |  | 4.28 |
| 1 month | 3.2 | | 5.2 |
| Current year | 2.21 | | 5.2 |
| 1 year | 1.44 | | 5.2 |
| 3 years | 1.44 | | 29.52 |
| 5 years | 1.44 | | 85.3 |
| 10 years | 1.44 | | 93 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Engsig
CEO | Chief Executive Officer | 54 | 2018-12-31 |
| President | 49 | 2016-12-31 | |
Harald Gurvin
DFI | Director of Finance/CFO | 51 | 2021-05-02 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | - | |
Trygve Lauvdal
BRD | Director/Board Member | 57 | - |
Susanne Stuffers
CHM | Chairman | 45 | 2025-04-22 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 3/27/25 | Buy | Company | 3,000,000 | 0.9187% | ||
| 12/20/24 | Buy | Director | 100,000 | 0.0306% | ||
| 12/20/24 | Sell | Director | 100,000 | 0.0306% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.95% | -6.41% | +161.39% | -85.60% | 144M | |
| -1.79% | -2.27% | +43.23% | +99.78% | 67.98B | |
| -2.51% | -0.43% | +34.45% | +81.93% | 64.94B | |
| -0.31% | +6.54% | -12.96% | +377.83% | 27.58B | |
| +0.86% | +1.65% | -7.74% | -13.58% | 26.06B | |
| -1.06% | -0.45% | +24.73% | +16.18% | 25.74B | |
| -0.88% | +1.56% | +23.92% | -17.97% | 20.09B | |
| -2.96% | -15.21% | +216.20% | +375.70% | 17.16B | |
| +0.16% | -1.49% | -6.97% | +548.74% | 14.92B | |
| -0.20% | +8.37% | +55.78% | +165.57% | 14.62B | |
| Average | -1.07% | -0.25% | +53.20% | +154.86% | 27.92B | |
| Weighted average by Cap. | -1.31% | +0.17% | +36.45% | +140.62% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 210M 22.58M 19.43M 18.28M 16.7M 31.24M 2.13B 31.32M 216M 83.82M 1.09B 84.78M 82.93M 3.52B |
| Net income | -209M -22.53M -19.39M -18.24M -16.66M -31.17M -2.13B -31.25M -216M -83.63M -1.09B -84.59M -82.75M -3.52B | 9.97M 1.07M 922K 868K 793K 1.48M 101M 1.49M 10.25M 3.98M 51.92M 4.02M 3.94M 167M |
| Net Debt | -484M -52.07M -44.8M -42.15M -38.51M -72.04M -4.92B -72.23M -498M -193M -2.52B -196M -191M -8.13B | -628M -67.58M -58.16M -54.72M -49.98M -93.5M -6.38B -93.76M -647M -251M -3.27B -254M -248M -10.55B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-07 | NOK 4.015 | -1.95% | 503,546 |
| 26-09-04 | NOK 4.095 | +0.37% | 997,829 |
| 26-09-03 | NOK 4.080 | -0.73% | 1,845,455 |
| 26-09-02 | NOK 4.110 | +0.86% | 4,187,115 |
| 26-09-01 | NOK 4.075 | -5.01% | 5,223,055 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VACC Stock
Select your edition
All financial news and data tailored to specific country editions
